IN THE SPOTLIGHT
The seventh conference on Clinical Trials on Alzheimer's Disease in Philadelphia last month covered everything from a sprinkling of new trial results to a new focus on tau PET imaging to a plea from former FDA honcho Rusty Katz that trialists stop obsessing over disease modification and aggressively pursue big therapeutic effects instead. Madolyn Rogers and Gabrielle Strobel close out their report on the meeting with a look at the role brain amyloid plays in AD, and a review of what new treatments may be in store for 2015.
ANT Congrès - 154 avenue de Lodève - 34070 Montpellier - France
E-mail : email@example.com
Tel : + 33 (0) 6 85 54 70 98
Fax : + 33 (0)4 67 10 92 23